4238

Novel Drug with Low Risk of Cross Resistance for the Treatment of Malaria.

Dzikowski Ron, HUJI, School of Medicine - IMRIC, Microbiology and Molecular Genetics
Nasereddin Abed, HUJI, School of Medicine - IMRIC

 

Background

Malaria is caused by unicellular Plasmodium parasites which are transmitted by the bite of mosquitoes. Although several medicines are available for prophylaxis and treatment of acute infection, their application is severely hampered by emerging resistances of the parasites. Novel drugs displaying a low risk of cross-resistance with established medicines are urgently needed.

With hundreds of millions infected patients worldwide and  hundreds of thousands  fatal outcomes annually, Malaria is one of the most dangerous infective diseases worldwide.

Our Innovation

  • Inhibition of the growth of erythrocytic stages of Plasmodium para-sites
  • No structural relation to established antimalarial drugs
  • Low risk of cross-resistance with established antimalarial drugs

Technology

The invented compound class against malaria inhibits the growth erythrocytic (human red blood cell) stages of plasmodium para- sites. Since the compounds are structurally unrelated to existing anti-malaria drugs, the risk of cross-resistance is low.

4238.jpg

Fig. 1:N-Unsubstituted 3,4-bis(indol-3-yl)cyclobut-3- ene-1,2-diones“

In fig. 1 the claimed Markush structure „N- Unsubstituted 3,4-bis(indol-3-yl) cyclobut-3- ene-1,2-diones as antimalarial drugs“ is de- picted, in which A(n), X, E, L, R, Y, and M(p) embody defined atoms or atom groups.

 

Patent Status

Granted US 10,287,271

Contact for more information:

Shani Bullock
VP, Business Development, Healthcare
+972-2-6586608